Operating Expenses (Quarterly)

Operating Expenses: The sum of all operating expenses for the given industry.

Takeda Pharmaceutical Co. (TAK) had Operating Expenses of $6.36B for the most recently reported fiscal quarter, ending 2025-06-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-06-30

Income Statement Financials
Revenue	$7.64B
Net Income	$857.28M
Cost of Goods Sold	$2.65B
Gross Profit	$4.98B
Operating Expenses	$6.36B
Operating Income	$1.27B
Non-Operating Income/Expense	$-234.16M
Pre-Tax Income	$1.04B
Normalized Pre-Tax Income	$1.04B
Income after Taxes	$857.53M
Income from Continuous Operations	$857.53M
Consolidated Net Income/Loss	$857.53M
Normalized Income after Taxes	$857.53M
EBIT	$1.27B
EBITDA	$2.53B
Weighted-Average Shares Outstanding (Basic)	3.13B
Weighted-Average Shares Outstanding (Diluted)	3.13B
Earnings per Share (EPS) (Basic)	$0.27
Earnings per Share (EPS) (Diluted)	$0.27
Balance Sheet Financials
Current Assets	$17.34B
Property, Plant, and Equipment	$13.50B
Long-Term Assets	$79.29B
Total Assets	$96.63B
Current Liabilities	$14.97B
Long-Term Debt	$28.53B
Long-Term Liabilities	$34.28B
Total Liabilities	$49.25B
Common Equity	$47.38B
Tangible Shareholders Equity	$-12.78B
Shareholders Equity	$47.38B
Common Shares Outstanding	3.12B
Cash Flow Statement Financials
Cash Flow from Operating Activities	$1.49B
Cash Flow from Investing Activities	$-229.03M
Cash Flow from Financial Activities	$-1.48B
Beginning Cash	$2.66B
End Cash	$2.42B
Increase/Decrease in Cash	$-242.22M
Stock-Based Compensation	$114.06M
Common Stock Dividends Paid	$-1.00B
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.16
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.38
Debt to Equity Ratio	0.66
Gross Margin	65.24%
Operating Margin	16.68%
EBIT Margin	16.68%
EBITDA Margin	--
Pre-Tax Profit Margin	13.61%
Profit Margin	11.23%
Free Cash Flow	$1.20B
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.08
Inventory Turnover	0.31
Receiveable Turnover	1.63
Days Sales in Receivables	55.26
Return on Equity	1.81%
Return on Tangible Equity	-6.71%
Return on Assets	0.89%
Return on Investments	1.13%
Book Value Per Share	$15.17
Free Cash Flow per Share	$0.38
Operating Cash Flow per Share	$0.47

Data from Zacks Investment Research, Inc.